FDA OKs New Nonstimulant Option for Adult ADHD
The FDA expanded the approval of viloxazine extended-release capsules (Qelbree) to include adults with ADHD, Supernus Pharmaceuticals announced. Now indicated for adults ages 18 and older, viloxazine is the first nonstimulant ADHD option for adults in 20 years. The agent was initially approved in April 2021 for children ages of 6 to 17.
Other Articles in this Edition
A clash over online Adderall prescriptions is raising new questions about telehealth
Adherence to ADHD Meds May Lower Unemployment Risk
Breaking Down the Stigma Surrounding ADHD
Cerebral’s Preferred Pharmacy Truepill Halts Adderall Prescriptions for All Customers
Mental Health Startup Cerebral To Stop ADHD Prescriptions For New Patients
FDA OKs New Nonstimulant Option for Adult ADHD
FDA Approves Xelstrym to Treat ADHD
Autism, ADHD and school absence are risk factors for self-harm, according to new study
Pitt research helps explain how Ritalin sharpens attention
‘Eye-Catching’ Smartphone App Could Make It Easy To Screen for Neurological Disease at Home
Video games could help treat cognitive disorders like depression and ADHD